Loading…
AN2 Therapeutics, Inc. is projected to rise to $6.31 by 2027, a +40% move from its current price of $4.50. ANTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.35 | $4.50 | $4.67 | +0.07% |
| Jul 13 | $4.29 | $4.51 | $4.74 | +0.13% |
| Jul 14 | $4.24 | $4.51 | $4.80 | +0.20% |
| Jul 15 | $4.20 | $4.51 | $4.84 | +0.27% |
| Jul 16 | $4.17 | $4.52 | $4.89 | +0.34% |
| Jul 17 | $4.14 | $4.52 | $4.93 | +0.40% |
| Jul 18 | $4.12 | $4.52 | $4.97 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.12 | $4.52 | $4.97 | +0.47% |
| Week 2 | $3.98 | $4.54 | $5.19 | +0.94% |
| Week 3 | $3.88 | $4.56 | $5.37 | +1.42% |
| Week 4 | $3.80 | $4.59 | $5.53 | +1.90% |
| Week 5 | $3.73 | $4.61 | $5.69 | +2.38% |
| Week 6 | $3.68 | $4.63 | $5.83 | +2.86% |
| Week 7 | $3.63 | $4.65 | $5.96 | +3.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB.
AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc. (ANTX) is trading at $4.42 with a market capitalization of $159.19M and ranks 3875 by market cap.
The stock sits in the healthcare space with a current price near the mid-range of its near-term outlook. The thirty-day range is $3.43 to $5.70, and the near-term price path is supported by bullish longer-term indicators. The current price is $4.42, and the market cap stands at $159.19M, with a rank of 3875 for market capitalization.
Forecast data imply a neutral stance in 2026 with an average price of $4.42, then a bullish trajectory through 2030 and beyond, reaching much higher averages in 2040 and 2050. The technical backdrop shows a bullish longer-term tilt, aided by a 30-day trading range that complements the multi-year upside potential.
A major floor 76.4% below — a decisive break under it would weaken the trend.
The nearest floor, 15.1% below — buyers have tended to step in here.
The nearest ceiling, 20.0% above — a clean break opens room to run.
A major ceiling 36.7% above — clearing it would confirm fresh momentum.
Key ANTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.45 | Buy | $4.52 | Sell |
| MA 10 | $4.64 | Sell | $4.60 | Sell |
| MA 20 | $4.80 | Sell | $4.64 | Sell |
| MA 50 | $4.59 | Sell | $4.44 | Buy |
| MA 100 | $3.89 | Buy | $3.86 | Buy |
| MA 200 | $2.53 | Buy | $3.07 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.22 | Neutral |
| Stoch RSI (14) | 19.17 | Buy |
| CCI (20) | -74.75 | Neutral |
| Williams %R (14) | -81.82 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -9.64 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 18.18 | Buy |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 37.71 | Neutral |
| Momentum (10) | -0.64 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 4.42 | Buy |
| ADX (14) | 14.01 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term picture shows bullish sentiment in the longer-range forecast, while the RSI14 sits at 40.
The stock’s 50-day simple moving average is $4.59 and the 200-day simple moving average is $2.45, with near-term support at $3.82 and resistance at $5.40.
The thirty-day range runs from $3.43 to $5.70, reflecting a relatively wide near-term trading band and suggesting meaningful volatility in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.03 | $4.50 | $6.32 | 0% | Neutral | |
| $4.88 | $6.31 | $8.71 | +40% | Bullish | |
| $6.90 | $9.26 | $13.39 | +106% | Bullish | |
| $7.89 | $10.93 | $16.36 | +143% | Bullish | |
| $8.48 | $12.08 | $18.64 | +168% | Bullish | |
| $9.37 | $13.68 | $21.67 | +204% | Bullish | |
| $9.40 | $14.07 | $22.81 | +213% | Bullish | |
| $10.94 | $16.74 | $27.72 | +272% | Bullish | |
| $12.94 | $20.25 | $34.17 | +350% | Bullish | |
| $14.80 | $23.64 | $40.61 | +425% | Bullish | |
| $19.79 | $34.82 | $64.40 | +674% | Bullish | |
| $45.43 | $95.07 | $195.49 | +20.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.03 | $4.50 | $5.50 | +0.00% |
| August 2026 | $3.83 | $4.56 | $5.60 | +1.35% |
| September 2026 | $3.98 | $4.78 | $5.96 | +4.90% |
| October 2026 | $4.17 | $5.05 | $6.37 | +5.59% |
| November 2026 | $4.08 | $4.98 | $6.34 | -1.45% |
| December 2026 | $4.01 | $4.92 | $6.32 | -1.16% |
Click any year to see its month-by-month ANTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ANTX to range from $1.03 to $6.32 through 2026. The $4.50 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ANTX price prediction for 2027 points to an average of $6.31 (low $4.88, high $8.71) — a potential gain of +40% on today's $4.50. Buyers look set to stay in control over this stretch.
In 2028, ANTX is projected to trade between $6.90 and $13.39, averaging $9.26 — a potential gain of +106% from today's $4.50. That is up +47% on the projected 2027 average. Momentum favours further upside here.
AN2 Therapeutics, Inc.'s 2029 outlook centres on $10.93, within a $7.89 to $16.36 range. That is up +18% on the projected 2028 average. That marks a +143% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ANTX could reach as high as $18.64, with a base case around $12.08 and support toward $8.48 — roughly +168% from $4.50. Momentum favours further upside here.
Expect ANTX to range from $9.37 to $21.67 through 2031. The $13.68 average target implies a +204% move from current prices. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ANTX price prediction for 2032 points to an average of $14.07 (low $9.40, high $22.81) — a potential gain of +213% on today's $4.50. Momentum favours further upside here.
In 2033, ANTX is projected to trade between $10.94 and $27.72, averaging $16.74 — a potential gain of +272% from today's $4.50. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
AN2 Therapeutics, Inc.'s 2034 outlook centres on $20.25, within a $12.94 to $34.17 range. That is up +21% on the projected 2033 average. That marks a +350% change versus current levels. Momentum favours further upside here.
By 2035, ANTX could reach as high as $40.61, with a base case around $23.64 and support toward $14.80 — roughly +425% from $4.50. Buyers look set to stay in control over this stretch.
Expect ANTX to range from $19.79 to $64.40 through 2040. The $34.82 average target implies a +674% move from current prices. That is up +47% on the projected 2035 average. Momentum favours further upside here.
The ANTX price prediction for 2050 points to an average of $95.07 (low $45.43, high $195.49) — a potential gain of +20.1x on today's $4.50. Buyers look set to stay in control over this stretch.
Investing $1,000 in ANTX today (≈ 222.222222 ANTX) could be worth
$21,126.12
+$20,126.12 (+2013%) by 2050 · US Dollar
Based on the average projected ANTX price of $95.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANTXwould be worth at today's price.
$1,000 invested in ANTX on Jul 10, 2025 (≈ 934.579393 ANTX) would be worth
$4,205.61
+$3,205.61 (+320.6%) today · 4.21× · US Dollar
Based on a ANTX entry price of $1.07 vs. today's $4.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.42 | $1,018.1 | +1.8% |
| 1 month ago | $4.2 | $1,071.43 | +7.1% |
| 3 months ago | $2.97 | $1,515.15 | +51.5% |
| 6 months ago | $1.14 | $3,947.37 | +294.7% |
| 1 year ago | $1.07 | $4,205.61 | +320.6% |
| All time (4.3y) ago | $15.4 | $292.21 | -70.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANTX forecast.
Our base-case forecast reaches $9.00 around 2028.
Implied market cap at $9.00: $324.15M
The multi-year forecast paints a clear bullish trajectory, with rising average prices and expanding ROIs across the horizon.
Looking at individual years, 2026 carries an average of $4.42 with an ROI of 0 and a neutral sentiment. From 2027 onward, sentiment shifts to bullish and the average climbs from $6.36 (2027) to $11.98 (2030), with ROIs of 43.8, 171 respectively. The path continues higher through 2035 ($23.73 average, ROI 436.9) and into 2040 ($33.76 average, ROI 663.9).
By 2050, the forecast shows an average of $94.55 with a max of $201.84 and an ROI of 2039.2, under a bullish outlook. The year-by-year ladder includes 2031 ($13.37, ROI 202.6), 2032 ($13.93, ROI 215.2), 2033 ($16.45, ROI 272.2), and 2034 ($19.90, ROI 350.3). The highest projected upper bound in 2050 is $201.84.
These figures are estimates and not guarantees; actual outcomes will depend on multiple factors. The forecast assumes continued advancement and market adoption within the asset’s therapeutic focus, but the range of possible results remains broad given the uncertainty inherent in clinical-stage biotech investing.
Tap a question to reveal the answer.
In 2030, the average price is forecast at $11.98, with a minimum of $8.23 and a maximum of $18.89. The forecasted ROI is 171, with a bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with the average price rising from $6.36 in 2027 to $94.55 by 2050 and ROIs listed as 43.8 in 2027 up to 2039.2 in 2050. The 2026 outlook is neutral with an average of $4.42 and ROI of 0.
The 2050 forecast suggests an average of $94.55 but the maximum is $201.84, indicating a path to or beyond $100 could exist on the high end by 2050, while the long-term average remains below $100 in 2040 and 2035 years.
The thirty-day range is $3.43 to $5.70.
AN2 Therapeutics, Inc. Community Discussion
0Share your AN2 Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.